Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences

Rhea-AI Summary

Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will present at three upcoming virtual investor conferences. The events include the RBC Capital Markets Global Healthcare Conference on May 18, Oppenheimer Rare & Orphan Disease Summit on May 21, and the Jefferies Virtual Global Healthcare Conference on June 1. Each presentation will feature a fireside chat followed by a Q&A session. An audio webcast will be available on their website, with replays lasting 90 days. Corbus focuses on developing medicines that target the endocannabinoid system, with its lead candidate being lenabasum.

Norwood, MA, May 11, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be presenting at three upcoming virtual investor conferences.

The following are the details for the conferences:

2021 RBC Capital Markets Global Healthcare Conference

• Event: Fireside Chat Discussion and Q&A
• Date and Time: Tuesday, May 18, 2021, at 3:40pm EST

Oppenheimer Rare & Orphan Disease Summit

• Event: Fireside Chat Discussion and Q&A
• Date and Time: Friday, May 21, 2021, at 9:55am EST

Jefferies Virtual Global Healthcare Conference

• Event: Fireside Chat Discussion and Q&A
• Date and Time: Tuesday, June 1, 2021, at 10:30am EST

An audio webcast of the presentations will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com. Replays will be available approximately one hour after each event and will be archived for 90 days following the event.

About Corbus 

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to provide an alternative to immunosuppressive medications in the treatment of chronic inflammatory and fibrotic diseases. Lenabasum is currently being evaluated in dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of other preclinical drug candidates from its endocannabinoid system platform.

Lenabasum is not approved for the treatment of any indication. For more information on Corbus’ clinical programs, please visit here.

For more information, visit http://www.corbuspharma.com/, and connect with us on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,” "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corbus Pharmaceuticals Contacts:

Ted Jenkins, Senior Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7745
Email: ir@corbuspharma.com

Lindsey Smith, Director, Investor Relations and Corporate Communications
Phone: +1 (617) 415-7749
Email: mediainfo@corbuspharma.com

FAQ

What is Corbus Pharmaceuticals' latest announcement regarding their conferences?

Corbus Pharmaceuticals announced that CEO Yuval Cohen will present at three virtual investor conferences in May and June 2021.

When is the RBC Capital Markets Global Healthcare Conference presentation?

The RBC Capital Markets Global Healthcare Conference presentation is scheduled for May 18, 2021, at 3:40 PM EST.

What is the focus of Corbus Pharmaceuticals as a clinical-stage company?

Corbus Pharmaceuticals focuses on developing novel medicines targeting the endocannabinoid system, with lenabasum as their lead candidate.

Where can I access the audio webcasts of Corbus Pharmaceuticals' presentations?

The audio webcasts of Corbus Pharmaceuticals' presentations can be accessed on their website under the Events section.

What is lenabasum being evaluated for?

Lenabasum is being evaluated for its efficacy in treating chronic inflammatory and fibrotic diseases such as dermatomyositis and systemic lupus erythematosus.